Biomarker-driven prescribing in oncology is playing an increasingly important role in various diseases, from indications in which its use is well entranced such as non-small-cell lung cancer (NSCLC), to indications that more recently incorporated the use of predicative biomarkers, such as malignant melanoma and ovarian cancer. However, these therapies are premium-priced and often face reimbursement restrictions in the EU5. Several recently EC-approved and emerging biomarker-targeted therapies are aiming to be incorporated into the treatment algorithm. Will these agents be met with increased reimbursement restrictions as the cost-consciousness of EU5 payers’ heightens in the current economic climate? This Access & Reimbursement module examines the factors that influence the success of current and emerging biomarker-driven therapies in NSCLC, ovarian cancer, and malignant melanoma. Based on insights from surveyed oncologists and interviewed payers across the EU5, this research explores how both parties shape the access environment for each disease, and how reimbursement decisions impact the prescribing and uptake of specific therapies at the brand level.

Table of contents

  • Biomarkers In Oncology - Access & Reimbursement - Detailed Expanded Analysis Biomarkers In Oncology: Malignant Melanoma, Non-Small-Cell Lung Cancer, Ovarian Cancer (EU5)
    • Actionable Recommendations to Optimize Market Access
      • Optimizing Market Access Opportunity for New Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer in the EU5
    • Successes and Stumbles
      • Successes Among Malignant Melanoma Biomarker-Targeted Therapies in the EU5
      • Successes Among NSCLC Biomarker-Targeted Therapies in the EU5
      • Successes Among Ovarian Cancer Biomarker-Targeted Therapies in the EU5
      • Stumbles Among Malignant Melanoma Biomarker-Targeted Therapies in the EU5
      • Stumbles Among NSCLC Biomarker-Targeted Therapies in the EU5
      • France: Reimbursement Successes and Stumbles
        • Germany: Reimbursement Successes and Stumbles
          • Italy: Reimbursement Successes and Stumbles
            • Spain: Reimbursement Successes and Stumbles
              • United Kingdom: Reimbursement Successes and Stumbles
              • Key Stakeholders in the Road to Market Access
                • France
                • Germany
                • Italy
                • Spain
                • United Kingdom
              • Key Market Access Roadblocks
                • France: Key Market Access Roadblocks
                • Germany: Key Market Access Roadblocks
                • Italy: Key Market Access Roadblocks
                • Spain: Key Market Access Roadblocks
                • United Kingdom: Key Market Access Roadblocks
              • Reimbursement Dynamics
                • France
                  • France: Crucial HTA Criteria
                  • France: P&R Drivers and Key HTA Considerations
                  • France: P&R Drivers and Key HTA Considerations
                  • France: HTA Review Details for Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • France: Lessons Learned and Key Takeaways
                  • France: Key Background Details of the Healthcare System
                  • France: P&R Process
                  • France: P&R Process
                  • France: Reimbursement Details and Mechanisms
                  • France: Prescribing Restrictions, Dispensation, and Monitoring
                • Germany
                  • Germany: Crucial HTA Criteria
                  • Germany: P&R Drivers and Key HTA Considerations
                  • Germany: P&R Drivers and Key HTA Considerations
                  • Germany: HTA Review Details for Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Germany: Lessons Learned and Key Takeaways
                  • Germany: Key Background Details of the Healthcare System
                  • Germany: P&R Process
                  • Germany: P&R Process
                  • Germany: Reimbursement Details and Mechanisms
                  • Germany: Prescribing Controls and Monitoring
                • Italy
                  • Italy: Crucial HTA Criteria
                  • Italy: P&R Drivers and Key HTA Considerations
                  • Italy: P&R Drivers and Key HTA Considerations
                  • Italy: HTA Review Details for Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC and Ovarian Cancer
                  • Italy: Lessons Learned and Key Takeaways
                  • Italy: Key Background Details of the Healthcare System
                  • Italy: P&R Process
                  • Italy: P&R Process
                  • Italy: Additional Funding Mechanisms for Off-Label Use
                  • Italy: Additional Funding Mechanisms for Off-Label Use
                • Spain
                  • Spain: Crucial HTA Criteria
                  • Spain: P&R Drivers and Key HTA Considerations
                  • Spain: P&R Drivers and Key HTA Considerations
                  • Spain: HTA Review Details for Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Spain: Lessons Learned and Key Takeaways
                  • Spain: Key Background Details of the Healthcare System
                  • Spain: P&R Process
                  • Spain: P&R Process
                  • Spain: HTA Bodies
                  • Spain: Autonomic Evaluation Committees (CAEs)
                  • Spain: Commissions for Pharmacy and Therapeutics (CFT)
                • United Kingdom
                  • United Kingdom: Crucial HTA Criteria
                  • United Kingdom: P&R Drivers and Key HTA Considerations
                  • United Kingdom: P&R Drivers and Key HTA Considerations
                  • United Kingdom: HTA Review Details for Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • United Kingdom: Lessons Learned and Key Takeaways
                  • United Kingdom: Key Background Details of the Healthcare System
                  • United Kingdom: P&R Process
                  • United Kingdom: P&R Process
                  • United Kingdom: Reimbursement Details and Budget Control
                  • United Kingdom: Reimbursement Details and Budget Control
                  • United Kingdom: Prescribing Controls and Monitoring
              • Pricing and Reimbursement, Policy, and Coverage: Impact on Prescribing
                • Prescriber Preferences for Biomarker-Targeted Therapies in Malignant Melanoma
                  • Prescriber Preferences for BRAF Inhibitors in Malignant Melanoma
                  • Patient Share of Treatments for First-Line BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma
                • Prescriber Preferences for Biomarker-Targeted Therapies in NSCLC
                  • Prescriber Preferences for EGFR Inhibitors in NSCLC
                  • Patient Share of Treatments for First-Line EGFR-Mutation-Positive Advanced/Metastatic NSCLC
                  • Patient Share of Tagrisso Used for the Treatment of Previously Treated EGFR-T790M-Mutation-Positive Metastatic NSCLC
                  • Prescriber Preferences for ALK Inhibitors in NSCLC
                  • Patient Share of Treatments for First-Line ALK-Translocation-Positive Advanced/Metastatic NSCLC
                • Prescriber Preferences for Biomarker-Targeted Therapies in Ovarian Cancer
                  • Prescriber Preferences for Therapies in the Maintenance Setting in Ovarian Cancer
                  • Patient Share of Treatments in the Maintenance Setting in Advanced Ovarian Cancer
                • Impact of Payer Policy on Prescribing of Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Influence of ASMR Ratings on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of Richtgrossen on Patient Access to Biomarker-Targeted Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of AIFA’s Monitoring Registry on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Influence of Spanish Regional Guidelines on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of NICE and CDF on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of Payer Policy on Prescribing of Therapies for BRAF-Mutation-Positive Malignant Melanoma
                  • Percentage of Malignant Melanoma Patients Not Receiving BRAF Inhibitors Due to Non-Clinical Factors
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in France
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Germany
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Italy
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Spain
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in the United Kingdom
                  • Impact of Payer Policy on Prescribing of Zykadia and Tagrisso for NSCLC
                  • Percentage of NSCLC Patients Not Receiving Biomarker-Targeted Agents Due to Non-Clinical Factors
                  • Impact of Payer Policy on Prescribing Lynparza for Ovarian Cancer
                  • Percentage of Ovarian Cancer Patients Not Receiving Lynparza due to Non-Clinical Factors
                • Top Prescribing Drivers of Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC and Ovarian Cancer
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in France
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Germany
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Italy
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Spain
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in the United Kingdom
              • Market Access Landscape for Emerging Therapies
                • Likely Impact of Emerging Biomarker-Targeted Therapies on Malignant Melanoma
                  • Anticipated Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in 2019
                  • Anticipated Prescribing of Tafinlar plus Mekinist, Zelboraf plus Cotellic, and Encorafenib plus Binimetinib for BRAF-Mutation-Positive Malignant Melanoma in 2019
                • Likely Impact of Emerging Biomarker-Targeted Therapies on NSCLC
                  • Anticipated Future Positioning of ALK Inhibitors in the NSCLC Treatment Algorithm
                  • Anticipated Prescribing of Tafinlar plus Mekinist for BRAF-V600-Mutation-Positive NSCLC in 2019
                  • Anticipated Prescribing of Keytruda for PD-L1-Expression-Positive NSCLC in 2019
                • Likely Impact of Emerging Biomarker-Targeted Therapies on Ovarian Cancer
                  • Anticipated Prescribing of Lynparza, Rucaparib and Niraparib in the Maintenance Setting for BRCA-Mutation-Positive and BRCA-Like Ovarian Cancer in 2019
                • Market Access Challenges for Emerging Biomarker-Targeted Therapies for Malignant Melanoma
                  • Factors Limiting Prescribing of Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                  • Factors Limiting Prescribing of Encorafenib plus Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                • Market Access Challenges for Emerging Biomarker-Targeted Therapies for NSCLC
                  • Factors Limiting Prescribing of Alecensa for Metastatic NSCLC by the End of 2019
                  • Factors Limiting Prescribing of Tafinlar plus Mekinist for Metastatic NSCLC by the End of 2019
                • Market Access Challenges for Emerging Biomarker-Targeted Therapies for Ovarian Cancer
                  • Factors Limiting Prescribing of Niraparib for Advanced Ovarian Cancer by the End of 2019
                  • Factors Limiting Prescribing of Rucaparib for Advanced Ovarian Cancer by the End of 2019
                • Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC and Ovarian Cancer
                  • France: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • France: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Germany: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Germany: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Italy: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Italy: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Spain: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Spain: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • United Kingdom: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • United Kingdom: Payer Opinion on Emerging Biomarker-Targeted Therapies for Malignant Melanoma, NSCLC, and Ovarian Cancer
              • Methodology
                • Abbreviations
                • Primary Research Design
                • Background of Payers and Payer-Advising KOLs
                • Physician Demographics and Practice Setting
                  • Years in Practice Post-Residency
                  • Average Number of Patients Treated per Year for Malignant Melanoma, NSCLC, and Ovarian Cancer
                  • Agents Prescribed Outside of a Clinical Trial for NSCLC
                  • Agents Prescribed Outside of a Clinical Trial for Malignant Melanoma
                  • Agents Prescribed Outside of a Clinical Trial for Advanced Ovarian Cancer
                  • Country Practice Location
                  • U.K. Practice Location
                  • Practice Location Within Community
              • Appendix
                • Key Biomarker-Targeted Therapies for Malignant Melanoma
                  • Profiles of Key Current Biomarker-Targeted Therapies for Malignant Melanoma in the EU5
                  • Binimetinib
                  • Array BioPharma's Binimetinib
                  • Encorafenib plus Binimetinib
                  • Array BioPharma's Encorafenib plus Binimetinib
                • Key Biomarker-Targeted Therapies for NSCLC
                  • Profiles of Key Current Biomarker-Targeted Therapies for NSCLC in the EU5
                  • Alecensa (Alectinib)
                  • Roche/Chugai's Alecensa (Alectinib)
                  • Tafinlar plus Mekinist (Dabrafenib plus Trematinib)
                  • Novartis' Tafinlar plus Mekinist (Dabrafenib plus Trematinib)
                  • Keytruda (Pembrolizumab)
                  • Merck & Co.'s Keytruda (Pembrolizumab)
                • Key Biomarker-Targeted Therapies for Ovarian Cancer
                  • Profiles of Key Current Biomarker-Targeted Therapies for Ovarian Cancer in the EU5
                  • Rucaparib
                  • Clovis Oncology's Rucaparib
                  • Niraparib
                  • Tesaro's Niraparib
                • Physician Survey Data
                  • Current Rate of Testing for Biomarkers in Patients with Advanced/Metastatic NSCLC, by Histology
                  • Current Rate of Definitive Results for Biomarker Tests in NSCLC
                  • Reasons Why Definitive Results Are Not Obtained for Biomarker Testing in Advanced/Metastatic NSCLC
                  • Sources of Funding for Biomarker Testing in Advanced/Metastatic NSCLC
                  • Current and Anticipated 2019 EGFR T790M Mutation Testing Rates in EGFR-TKI-Pretreated Patients with NSCLC
                  • Factors Restricting EGFR Expression Testing in Advanced/Metastatic NSCLC
                  • Factors Restricting EGFR T790M Mutation Testing in Advanced/Metastatic NSCLC
                  • Factors Restricting ALK Translocation Testing in Advanced/Metastatic NSCLC
                  • Factors Restricting PD-L1 Expression Testing in Advanced/Metastatic NSCLC
                  • Funding of Recently Approved NSCLC Therapies in the EU5
                  • Percentage of NSCLC Patients Not Receiving Biomarker-Targeted Agents Due to Non-Clinical Factors
                  • Patient Share of Treatments for First-Line EGFR-Mutation-Positive Advanced/Metastatic NSCLC
                  • Patient Share of Treatments for First-Line ALK-Translocation-Positive Advanced/Metastatic NSCLC
                  • Factors Associated with Prescribing of Giotrif in Germany
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in France
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Germany
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Italy
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in Spain
                  • Factors Influencing Prescribing of Therapies for Newly Diagnosed EGFR-Mutation-Positive and ALK-Translocation-Positive Advanced/Metastatic NSCLC in the United Kingdom
                  • Most Frequently Prescribed Sequential Treatment for EGFR-Mutation-Positive Metastatic NSCLC in France
                  • Most Frequently Prescribed Sequential Treatment for EGFR-Mutation-Positive Metastatic NSCLC in Germany
                  • Most Frequently Prescribed Sequential Treatment for EGFR-Mutation-Positive Metastatic NSCLC in Italy
                  • Most Frequently Prescribed Sequential Treatment for EGFR-Mutation-Positive Metastatic NSCLC in Spain
                  • Most Frequently Prescribed Sequential Treatment for EGFR-Mutation-Positive Metastatic NSCLC in the United Kingdom
                  • Patient Share of Tagrisso Used for the Treatment of Previously Treated EGFR-T790M-Mutation-Positive Metastatic NSCLC
                  • Factors Restricting Prescribing of Tagrisso in EGFR-T790M-Mutated, EGFR-TKI-Treated Advanced/Metastatic NSCLC in France
                  • Factors Restricting Prescribing of Tagrisso in EGFR-T790M-Mutated, EGFR-TKI-Treated Advanced/Metastatic NSCLC in Germany
                  • Factors Restricting Prescribing of Tagrisso in EGFR-T790M-Mutated, EGFR-TKI-Treated Advanced/Metastatic NSCLC in Italy
                  • Factors Restricting Prescribing of Tagrisso in EGFR-T790M-Mutated, EGFR-TKI-Treated Advanced/Metastatic NSCLC in Spain
                  • Factors Restricting Prescribing of Tagrisso in EGFR-T790M-Mutated, EGFR-TKI-Treated Advanced/Metastatic NSCLC in the United Kingdom
                  • Most Frequently Prescribed Sequential Treatment for ALK-Translocation-Positive Metastatic NSCLC in France
                  • Most Frequently Prescribed Sequential Treatment for ALK-Translocation-Positive Metastatic NSCLC in Germany
                  • Most Frequently Prescribed Sequential Treatment for ALK-Translocation-Positive Metastatic NSCLC in Italy
                  • Most Frequently Prescribed Sequential Treatment for ALK-Translocation-Positive Metastatic NSCLC in Spain
                  • Most Frequently Prescribed Sequential Treatment for ALK-Translocation-Positive Metastatic NSCLC in the United Kingdom
                  • Factors Restricting Prescribing of Zykadia in ALK-Translocation-Positive, Xalkori-Treated Advanced/Metastatic NSCLC in France
                  • Factors Restricting Prescribing of Zykadia in ALK-Translocation-Positive, Xalkori-Treated Advanced/Metastatic NSCLC in Germany
                  • Factors Restricting Prescribing of Zykadia in ALK-Translocation-Positive, Xalkori-Treated Advanced/Metastatic NSCLC in Italy
                  • Factors Restricting Prescribing of Zykadia in ALK-Translocation-Positive, Xalkori-Treated Advanced/Metastatic NSCLC in Spain
                  • Factors Restricting Prescribing of Zykadia in ALK-Translocation-Positive, Xalkori-Treated Advanced/Metastatic NSCLC in the United Kingdom
                  • Anticipated Future Positioning of ALK Inhibitors in the NSCLC Treatment Algorithm
                  • Reasons for Not Prescribing Alecensa for Metastatic NSCLC by the End of 2019
                  • Factors Limiting Prescribing of Alecensa for Metastatic NSCLC by the End of 2019
                  • Anticipated Prescribing of Tafinlar plus Mekinist for BRAF-V600-Mutation-Positive NSCLC in 2019
                  • Reasons for Not Prescribing Tafinlar plus Mekinist for Metastatic NSCLC by the End of 2019
                  • Factors Limiting Prescribing of Tafinlar plus Mekinist for Metastatic NSCLC by the End of 2019
                  • Oncologists' Opinion on Prescribing of BRAF/MEK Inhibitors for Metastatic NSCLC in France
                  • Oncologists' Opinion on Prescribing of BRAF/MEK Inhibitors for Metastatic NSCLC in Germany
                  • Oncologists' Opinion on Prescribing of BRAF/MEK Inhibitors for Metastatic NSCLC in Italy
                  • Oncologists' Opinion on Prescribing of BRAF/MEK Inhibitors for Metastatic NSCLC in Spain
                  • Oncologists' Opinion on Prescribing of BRAF/MEK Inhibitors for Metastatic NSCLC in the United Kingdom
                  • Oncologists' Opinion on Prescribing of Keytruda for PD-L1-Expression-Positive, Previously Treated Metastatic NSCLC in France
                  • Oncologists' Opinion on Prescribing of Keytruda for PD-L1-Expression-Positive, Previously Treated Metastatic NSCLC in Germany
                  • Oncologists' Opinion on Prescribing of Keytruda for PD-L1-Expression-Positive, Previously Treated Metastatic NSCLC in Italy
                  • Oncologists' Opinion on Prescribing of Keytruda for PD-L1-Expression-Positive, Previously Treated Metastatic NSCLC in Spain
                  • Oncologists' Opinion on Prescribing of Keytruda for PD-L1-Expression-Positive, Previously Treated Metastatic NSCLC in the United Kingdom
                  • Anticipated Prescribing of Keytruda for PD-L1-Expression-Positive NSCLC in 2019
                  • Current Rate of Testing for BRAF Mutations in Patients with Malignant Melanoma
                  • Current Rate of Definitive Results for BRAF Mutation Tests in Malignant Melanoma
                  • Reasons Why Definitive Results Are Not Obtained for BRAF Mutation Testing in Malignant Melanoma
                  • Factors Restricting BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma in France
                  • Factors Restricting BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma in Germany
                  • Factors Restricting BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma in Italy
                  • Factors Restricting BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma in Spain
                  • Factors Restricting BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma in the United Kingdom
                  • Current and Anticipated 2019 Biomarker Testing Rates in Unresectable/Metastatic Malignant Melanoma
                  • Sources of Funding for BRAF Mutation Testing in Unresectable/Metastatic Malignant Melanoma
                  • Sources of Funding for NRAS Mutation Testing in Unresectable/Metastatic Malignant Melanoma
                  • Sources of Funding for PD-L1 Expression Testing in Unresectable/Metastatic Malignant Melanoma
                  • Sources of Funding for MEK1 Mutation Testing in Unresectable/Metastatic Malignant Melanoma
                  • Sources of Funding for c-Kit Mutation Testing in Unresectable/Metastatic Malignant Melanoma
                  • Patient Share of Treatments for First-Line BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma
                  • Most Frequently Prescribed Sequential Treatment for BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma in France
                  • Most Frequently Prescribed Sequential Treatment for BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma in Germany
                  • Most Frequently Prescribed Sequential Treatment for BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma in Italy
                  • Most Frequently Prescribed Sequential Treatment for BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma in Spain
                  • Most Frequently Prescribed Sequential Treatment for BRAF-Mutation-Positive Unresectable/Metastatic Malignant Melanoma in the United Kingdom
                  • Percentage of Malignant Melanoma Patients Not Receiving BRAF Inhibitors Due to Non-Clinical Factors
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in France
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Germany
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Italy
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in Spain
                  • Non-Clinical Factors Restricting Prescribing of Biomarker-Targeted Agents for BRAF-Mutation-Positive Malignant Melanoma in the United Kingdom
                  • Funding of Cotellic and Zelboraf Combination Therapy in Italy and Spain
                  • Oncologists' Opinion on Prescribing of Tafinlar plus Mekinist and Zelboraf plus Cotellic for BRAF-Mutation-Positive Malignant Melanoma in France
                  • Oncologists' Opinion on Prescribing of Tafinlar plus Mekinist and Zelboraf plus Cotellic for BRAF-Mutation-Positive Malignant Melanoma in Germany
                  • Oncologists' Opinion on Prescribing of Tafinlar plus Mekinist and Zelboraf plus Cotellic for BRAF-Mutation-Positive Malignant Melanoma in Italy
                  • Oncologists' Opinion on Prescribing of Tafinlar plus Mekinist and Zelboraf plus Cotellic for BRAF-Mutation-Positive Malignant Melanoma in Spain
                  • Oncologists' Opinion on Prescribing of Tafinlar plus Mekinist and Zelboraf plus Cotellic for BRAF-Mutation-Positive Malignant Melanoma in the United Kingdom
                  • Anticipated Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in 2019
                  • Reasons for Not Prescribing Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                  • Factors Limiting Prescribing of Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                  • Oncologists' Opinion on Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in France
                  • Oncologists' Opinion on Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in Germany
                  • Oncologists' Opinion on Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in Italy
                  • Oncologists' Opinion on Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in Spain
                  • Oncologists' Opinion on Prescribing of Binimetinib for NRAS-Mutation-Positive Malignant Melanoma in the United Kingdom
                  • Anticipated Prescribing of Tafinlar plus Mekinist, Zelboraf plus Cotellic, and Encorafenib plus Binimetinib for BRAF-Mutation-Positive Malignant Melanoma in 2019
                  • Reasons for Not Prescribing Encorafenib plus Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                  • Factors Limiting Prescribing of Encorafenib plus Binimetinib for Unresectable/Metastatic Malignant Melanoma by the End of 2019
                  • Opinion of Encorafenib plus Binimetinib and BRAF/MEK Inhibitor Combination Therapy in Malignant Melanoma
                  • Current Rate of Testing for BRCA1/2 Mutation in Patients with Advanced Ovarian Cancer
                  • Sources of Funding for BRCA1/2 Mutation Testing in Advanced Ovarian Cancer
                  • Factors Restricting BRCA1/2 Mutation Testing in Advanced Ovarian Cancer in France
                  • Factors Restricting BRCA1/2 Mutation Testing in Advanced Ovarian Cancer in Germany
                  • Factors Restricting BRCA1/2 Mutation Testing in Advanced Ovarian Cancer in Italy
                  • Factors Restricting BRCA1/2 Mutation Testing in Advanced Ovarian Cancer in Spain
                  • Factors Restricting BRCA1/2 Mutation Testing in Advanced Ovarian Cancer in the United Kingdom
                  • Funding of Lynparza in Italy
                  • Patient Share of Treatments in the Maintenance Setting in Advanced Ovarian Cancer
                  • Percentage of Ovarian Cancer Patients Not Receiving Lynparza due to Non-Clinical Factors
                  • Factors Restricting Prescribing of Lynparza in BRCA1/2-Mutation-Positive Advanced Ovarian Cancer in France
                  • Factors Restricting Prescribing of Lynparza in BRCA1/2-Mutation-Positive Advanced Ovarian Cancer in Germany
                  • Factors Restricting Prescribing of Lynparza in BRCA1/2-Mutation-Positive Advanced Ovarian Cancer in Italy
                  • Factors Restricting Prescribing of Lynparza in BRCA1/2-Mutation-Positive Advanced Ovarian Cancer in Spain
                  • Factors Restricting Prescribing of Lynparza in BRCA1/2-Mutation-Positive Advanced Ovarian Cancer in the United Kingdom
                  • Anticipated BRCA1/2 Mutation Testing Rates in Advanced Ovarian Cancer in 2019
                  • Anticipated Prescribing of Lynparza, Rucaparib and Niraparib in the Maintenance Setting for BRCA-Mutation-Positive and BRCA-Like Ovarian Cancer in 2019
                  • Reasons for Not Prescribing Niraparib for Advanced Ovarian Cancer by the End of 2019
                  • Reasons for Not Prescribing Rucaparib for Advanced Ovarian Cancer by the End of 2019
                  • Factors Limiting Prescribing of Niraparib for Advanced Ovarian Cancer by the End of 2019
                  • Factors Limiting Prescribing of Rucaparib for Advanced Ovarian Cancer by the End of 2019
                  • Oncologists' Opinion on Niraparib and Rucaparib in Advanced Ovarian Cancer in France
                  • Oncologists' Opinion on Niraparib and Rucaparib in Advanced Ovarian Cancer in Germany
                  • Oncologists' Opinion on Niraparib and Rucaparib in Advanced Ovarian Cancer in Italy
                  • Oncologists' Opinion on Niraparib and Rucaparib in Advanced Ovarian Cancer in Spain
                  • Oncologists' Opinion on Niraparib and Rucaparib in Advanced Ovarian Cancer in the United Kingdom
                  • Influence of ASMR Ratings on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of Richtgrossen on Patient Access to Biomarker-Targeted Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of AIFA’s Monitoring Registry on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Influence of Spanish Regional Guidelines on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies
                  • Impact of NICE and CDF on Prescribing of Malignant Melanoma, NSCLC, and Ovarian Cancer Therapies

            Author(s): Izabela Ammermann, PhD

            Izabela Ammermann, Ph.D., M.Sc., is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a Ph.D. in molecular biology from the Technical University of Munich and a M.Sc. in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.


            Related Reports

            Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

            The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

            View Details

            Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

            The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

            View Details

            Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

            Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.

            View Details

            Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020

            Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...

            View Details